PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Gray, Richard G.
TI  - ATLAS: 10 versus 5 Years of Adjuvant Tamoxifen in ER-Positive Disease
DP  - 2013 Mar 01
TA  - MD Conference Express
PG  - 11--12
VI  - 12
IP  - 20
4099  - http://mdc.sagepub.com/content/12/20/11.2.short
4100  - http://mdc.sagepub.com/content/12/20/11.2.full
AB  - Treatment with tamoxifen for 5 years has substantially reduced the risk of breast cancer recurrence and death throughout the first 15 years after diagnosis of estrogen receptor (ER)-positive early breast cancer [Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet 2011]. The Adjuvant Tamoxifen: Longer Against Shorter [ATLAS] trial compared the effects of continuing tamoxifen for a total of 10 years with stopping after the standard 5 years of treatment. This article presents data from the ATLAS trial on the effect of tamoxifen on 15-year survival [Davies C et al. Lancet 2012].